NEW YORK (GenomeWeb) – Paradigm and Forma Therapeutics today announced a multiyear partnership to identify predictive response biomarkers and measure pharmacodynamic activity for two of Forma's advanced preclinical candidates.

Paradigm will use its technology to evaluate the potential of molecular markers to predict clinical outcomes, which would enable Forma "to efficiently match our drugs with high-quality molecular assays to realize a personalized approach to cancer drug development," Forma President and CEO Steven Tregay said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.